Introduction
Antibody-mediated rejection (AMR) is a rare condition, but serious in patients with organ transplantation. It is caused by the formation of antibodies against donor human leucocyte antigens (HLAs) on the endothelial layer of the cardiac allograft. 1 Cardiac AMR may manifest early within the first weeks after heart transplantation, but also late after months to years following transplantation. Clinical presentation varies from mild heart failure to cardiogenic shock. Because the clinical symptoms are not specific, AMR of cardiac allograft is difficult to diagnose, but even more difficult to treat, as there are no Class 1 recommendations for standardized treatment.
Timeline Case presentation
A 47-year-old male patient was admitted to our clinic in December 2017 for routine heart catheter. He had a history of severe ischaemic cardiomyopathy since 2012 and had been supported by the left ventricular assist device (LVAD) Heart Mate II for 2 years. Due to recurrent driveline infections, he underwent heart transplantation with an HLA-compatible heart in October 2014. Since then, he has been regularly examined according to our routine post-transplant surveillance protocol every 3-6 months. The left ventricular ejection fraction (LVEF) remained stable at 55% since transplantation. His immunosuppressive regimen included cyclosporine A and everolimus, and he had no signs of rejections since transplantation. The current hospital admission was scheduled for evaluation of cardiac allograft vasculopathy. On admission, the patient reported of new-onset of fatigue and dyspnoea during ordinary physical exertion [New York Heart Association (NYHA) Class II] a few weeks before. Physical examination at rest revealed a heart rate of 88 b.p.m. and blood pressure of 105/75 mmHg. Lung auscultation did not present rales, and there were no peripheral edema. However, echocardiographic assessment showed worsening of the LVEF to 30-35%. Serum pro B-type natriuretic peptide (proBNP) was increased up to 10 000 pg/mL (normal range < 125 pg/mL) in contrast to 250 pg/mL 6 months earlier.
Cardiac allograft vasculopathy was excluded by coronary angiography. On suspicion of rejection, myocardial biopsy was performed and donor-specific antibodies (DSA) were evaluated.
In contrast to 3 months earlier, where no DSA were detected, serological testing was now positive for the HLA-A, HLA-B, HLA-C, HLA-DRB1, and HLA-DQB1 genes ( Figure 1A) , suggesting de novo DSA. Accordingly, endomyocardial biopsy showed histological and immunopathologic evidence for AMR of the cardiac allograft with a high number of CD68 macrophages and C4d positive deposits as well as MHC Class II molecules on capillary endothelial cells of the allograft. The biopsy did not show any evidence for acute cellular rejection (ISHLT classification: Grade 0R). Based on these findings, the diagnosis of late AMR of the cardiac allograft was made.
In order to prevent further deterioration of the allograft function, high-dose prednisolone was administered immediately after biopsy. Additionally, plasmapheresis was initiated for 5 days combined with intravenous Gamma Globulin (IVIg). The prior maintenance immunosuppression regimen with cyclosporine A and everolimus was continued. However, LVEF estimated by echocardiography remained 30-35%. Therefore, rituximab (375 mg/m 2 weekly) was added for 4 weeks ( Figure 1B) . Unfortunately, DSA levels remained at a high level, and we replaced plasmapheresis by immunoadsorption, assuming that this procedure may be more effective in removing DSA. 1 Additionally, we administered another round of IVIg. Notably, under this strategy, and 35 days after initiating the treatment, LVEF improved to 50% and proBNP decreased to 1200 pg/mL ( Figure 1C) . However, there was no significant decline of DSA levels ( Figure 1A) . Therefore, we decided to add bortezomib. Over the next weeks, LVEF and proBNP remained stable, and the patient improved to NYHA Class I. However, even with additional immunoadsorption three times a week, DSA levels remained high. Following 8 rounds of Currently, 3 years after the diagnosis of cardiac AMR, graft function continues to be nearly normal, while DSA levels remain at a constant elevated level. There is no evidence for transplant vasculopathy.
Discussion
Antibody-mediated rejection in cardiac transplantation is caused by the formation of antibodies against donor HLAs on the endothelial layer of the cardiac allograft. 1 Antibodies induce activation and deposition of complement components, resulting in activation of the innate and adaptive immune system, inflammatory processes, and eventually allograft dysfunction. For yet unknown reasons, patients undergoing heart transplantation from LVAD (bridge-to-transplant), as was the case in our patient, are at increased risk to develop cardiac AMR. 1 Cardiac AMR may manifest early within the first weeks after transplantation but also late after months to years following transplantation resulting in mild heart failure to cardiogenic shock. While patients with early cardiac AMR are less affected and seem to have survival rates comparable to transplant recipients without AMR, late cardiac AMR is frequently associated with graft dysfunction, fulminant forms of cardiac allograft vasculopathy, and a high mortality rate. 2, 3 Nevertheless, AMR of cardiac allografts remains difficult to diagnose and to treat.
The general principles in the treatment of AMR consist of four pillars: removing circulating alloantibodies, reducing production of additional alloantibodies, suppressing T-cell and B-cell responses, and inhibiting of complement. However, Class 1 recommendations for standardized treatment protocol or treatment duration of cardiac AMR still do not exist.
In our case, we applied corticosteroid pulse regimen as the first approach. In order to remove circulating DSA as quickly as possible, plasmapheresis and subsequently immunoadsorption were initiated to mechanically remove circulating antibodies. Additionally, we added IVIg, although its effectiveness in the treatment of acute AMR has never been systematically studied. However, we assumed that it could inhibit the complement system, neutralize autoantibodies and cytokines and down-regulate B-cell receptors. The treatment was then escalated by rituximab to deplete B cells and to inhibit de novo production of donor-specific HLA antibodies. Multiple case reports have previously demonstrated the successful use of rituximab as a 'salvage therapy' for refractory AMR, and in a series of eight patients with AMR treated with rituximab monotherapy, left ventricular function recovered to normal in all patients. 4 Although only limited experience existed with bortezomib in cardiac AMR, we decided to applicate it to our patient, as DSA remained high despite the aggressive therapy. Interestingly, this did not affect the DSA level, which remained at a moderate elevated level after an initial fall. This phenomenon has been previously described as 'accommodation', which refers to an acquired resistance of an organ graft to humoral injury and rejection. 5 In summary, we presented an effective treatment protocol for late AMR with severe allograft dysfunction. Notably, despite our strategy to 'hit hard and early', DSA levels remained at a high level, suggesting that continuous monitoring of DSA may not be a suitable parameter Antibody-mediated rejection
